Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 23, 2019 07:00 ET | Source: FibroGen, Inc

FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease

SAN FRANCISCO, Dec. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for...
October 11, 2019 10:58 ET | Source: FibroGen, Inc

Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019

SAN FRANCISCO, Oct. 11, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that results from the global Phase 3 roxadustat clinical program will be presented at the American...
June 07, 2018 07:00 ET | Source: FibroGen, Inc

FibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program for Roxadustat in Anemia Associated with Chronic Kidney Disease

SAN FRANCISCO, June 07, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced the completion of patient enrollment in the Phase 3 studies supporting the...
July 25, 2016 21:00 ET | Source: FibroGen, Inc.

Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan

TOKYO and SAN FRANCISCO, July 25, 2016 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE:4503) (“Astellas”) and FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), today announced the dosing of the first...